The role of anti-FGFR therapy in pancreatic cancer with aberrant FGFR expression: a scoping review
Creators: name: Orlandi, Elena
name: Guasconi, Massimo
name: Trubini, Serena
name: Vecchia, Stefano
name: giuffrida, mario
name: Proietto, Manuela
name: Anselmi, Elisa
name: Romboli, Andrea
Publisher: name: figshare
Year: 2024
Subjects: classificationCode: 321104
subject: Cancer therapy (excl. chemotherapy and radiation therapy)
classificationCode: 321108
subject: Molecular targets
classificationCode: 321111
subject: Solid tumours

description: <b><i>AIM</i></b>In order to provide a comprehensive picture of treatement against pancreatic cancer with FGFR alteration, this scoping review aims to identify and present the available information concerning preclinical or clinical study and results of anti-FGFR (TKI or FGFR specific inhibitors) in pancreatic cancer harboring FGFR alterations, and regarding clinical study in terms of population analyzed, toxicity and efficacy. <b><i>ELEGIBILITY CRITERIA</i></b><b>Participants </b>We will include patients with a diagnosis of pancreatic cancer of any age, male and female, with a proven FGFR alteration. <b>Concept </b>We will include studies that analyzed anti-FGFR treatment, specific FGFR inhibitors selectively target FGFR isoforms, potentially reducing side effects associated with broader activity and providing a more focused approach to disrupting FGFR-driven oncogenic processes. <b>Context </b>Study selection will be guided by the researcher’s inclusion criterion for articles in which target therapy will be directed on dysregulation of FGFR signaling with aberrant activation of FGFR pathways.<b>Types of Sources</b> This scoping review will systematically consider randomized controlled trials, non-randomized controlled trials, before and after studies and interrupted time-series studies. In addition, analytical observational studies including prospective and retrospective cohort studies, case-control studies and analytical cross-sectional studies will be considered for inclusion. This review will also consider descriptive observational study designs including case series, individual case reports and descriptive cross-sectional studies for inclusion. In addition, systematic reviews that meet the inclusion criteria will also be considered, depending on the research question. Text and opinion papers will also be considered for inclusion in this scoping review. gray literature will also be included as long as the research design is clearly recognizable.There will be no date limitations or language restrictions. The reference lists of retrieved studies will be reviewed to identify additional reports of relevant trials. <b><i>SEARCH STRATEGY</i></b>It will be carried out a search on the online databases PubMed, Embase, Cochrane, Scopus, Web of Science, EBSCO Open Dissertation databases and the CENTRAL registry. An initial search strategy was launched in PubMed, then the strategy was supplemented and modified based on the initial results obtained. The search strategy used for PubMed is reported the strategies used for the other databases were derived from that for PubMed. ("Pancreatic Neoplasms"[Mesh] OR "Pancreas carcinoma"[Title/Abstract:~5] OR "Pancreas carcinomas"[Title/Abstract:~5] OR "Pancreas neoplasm"[Title/Abstract:~5] OR "Pancreas neoplasms"[Title/Abstract:~5] OR "Pancreas Cancer"[Title/Abstract:~5] OR "Pancreas Cancers"[Title/Abstract:~5] OR "Pancreatic Carcinoma"[Title/Abstract:~5] OR "Pancreatic Carcinomas"[Title/Abstract:~5] OR "Pancreatic neoplasm"[Title/Abstract:~5] OR "Pancreatic neoplasms"[Title/Abstract:~5] OR "Pancreatic Cancer"[Title/Abstract:~5] OR "Pancreatic Cancers"[Title/Abstract:~5] OR "neoplasia pancreas"[Title/Abstract:~5] OR "neoplastic pancreas"[Title/Abstract:~5] OR "neoplastic pancreatic"[Title/Abstract:~5] OR "pancreas tumorigenesis"[Title/Abstract:~5] OR "pancreatic tumorigenesis"[Title/Abstract:~5] OR "pancreas tumor"[Title/Abstract:~5] OR "pancreas tumors"[Title/Abstract:~5] OR "pancreas tumour"[Title/Abstract:~5] OR "pancreas tumours"[Title/Abstract:~5] OR "pancreatic tumor"[Title/Abstract:~5] OR "pancreatic tumors"[Title/Abstract:~5] OR "pancreatic tumour"[Title/Abstract:~5] OR "pancreatic tumours"[Title/Abstract:~5]) AND ("Receptors, Fibroblast Growth Factor"[Mesh] OR FGFR[Title/Abstract] OR "Fibroblast Growth Factor Receptor*"[Title/Abstract] OR "FGF Receptor*"[Title/Abstract]) <b><i>STUDY SELECTION</i></b>After removing duplicates, two researchers will independently review the title and abstract of the studies to determine which ones to include. Following that, the same researchers will independently assess the full texts. Any disagreements will be settled by two additional researchers.<b><i>DATA EXTRACTION</i></b>The data extraction table will be set up in advance, and will be used to gather information from studies and related literature. Data on the title, authors, journal, publication year, country in which the study was performed, study design, characteristics of the population, concept and context, and key findings relevant to the scoping review research questions will be included.<b><i>DATA ANALYSIS AD PRESENTATION OF RESULTS</i></b> The analysis and presentation of results will follow the JBI guidelines for scoping reviews. Results might also be displayed using charts and figures. The most effective method for presenting data will be determined based on the findings at the conclusion of the study.